<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002222</url>
  </required_header>
  <id_info>
    <org_study_id>MCS-2-US-c</org_study_id>
    <nct_id>NCT01002222</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)</brief_title>
  <acronym>MCS-2-US-c</acronym>
  <official_title>Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Na√Øve Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Ever Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Ever Bio-Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who
      have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be
      eligible for this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label extension study is designed to further assess the long-term safety and
      efficacy of MCS-2. Subjects who have completed the 12-week treatment and procedures under the
      protocol MCS-2-TWN-a will be eligible for another 40 weeks of MCS-2 treatment at the optimal
      dose selected after the phase 2b part of MCS-2-US-a. Subjects are limited to those who are
      currently not being treated medically for BPH or LUTS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAE)</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in International Prostate Symptom Score (I-PSS)</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in urine flow rate</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in serum lycopene levels</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>MCS-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS-2</intervention_name>
    <description>15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.</description>
    <arm_group_label>MCS-2</arm_group_label>
    <other_name>MUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has completed 12 weeks of treatment under the protocol MCS-2-US-a.

          -  Subject is able to understand and willing to conform to the study procedures and has
             signed the informed consent form for participation in this extension study.

        Exclusion Criteria:

          -  Subject has severe LUTS at the last visit under the protocol MCS-2-US-a.

          -  Subject is considered ineligible for the study by the investigator(s).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan J Pantuck, MD, MS, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>March 1, 2015</last_update_submitted>
  <last_update_submitted_qc>March 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>MCS-2</keyword>
  <keyword>Multi-Carotenoids</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>International prostate symptom score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

